Brigatinib, was initially used to treat ALK-positive metastatic NSCLC intolerant to Crizotinib [123], and was later found to have inhibitory activity against ROS1 fusion-positive tumors, making it a next-generation tyrosine kinase [124]. Here, ALK is linked to non-small cell lung carcinoma.